Lancet study warns Trump drug pricing plan may raise EU costs, delay therapies

A Lancet study warns that Trump's demand for higher European drug prices to fund US reductions could reshape global pharma markets, potentially raising costs and delaying therapy launches in Europe. The claim is based on a modeling study, not observed market changes, so its real-world impact remains uncertain. This matters because it signals a potential policy-driven shift in global drug pricing dynamics.